Peter Attia MD - Most promising molecules for longevity | Peter Attia and Steve Austad
The conversation explores the potential of existing molecules, such as metformin and rapamycin, for geroprotection. While rapamycin shows promise in mouse studies, metformin's human data is more compelling, though its effectiveness in non-diabetic individuals remains uncertain. The speaker suggests that combinations of these drugs might be more beneficial. The safety of metformin is highlighted, but challenges exist in conducting trials on healthy individuals due to FDA regulations. The discussion also touches on the design of longevity trials, suggesting starting with doses tested for enhancing vaccine responses. The potential of SGLT2 inhibitors and NAD precursors is acknowledged, but more data is needed. The importance of human biomarkers for future research is emphasized, as they could provide insights into the effects of these drugs on various health outcomes.
Key Points:
- Rapamycin shows potential in mouse studies, but metformin has more compelling human data.
- Combining drugs like rapamycin and metformin might enhance geroprotective effects.
- Metformin is safe and widely used, but its effectiveness in healthy individuals is uncertain.
- Designing longevity trials should consider doses tested for enhancing vaccine responses.
- Human biomarkers are crucial for advancing research on drug effects on health outcomes.